



Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis

Mingzhou Gao^{1†}, Dongmei Gao^{1†}, Hui Sun^{2†}, Xunshu Cheng¹, Li An³ and Mingqi Qiao^{1*}

¹ College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China, ² School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China, ³ Traditional Chinese Medicine Department, Jinan Central Hospital, Jinan, China

OPEN ACCESS

Edited by:

Wulf Rössler, Charité – Universitätsmedizin Berlin, Germany

Reviewed by:

Katja Maria Schmalenberger, Heidelberg University, Germany Erika Comasco, Uppsala University, Sweden

> *Correspondence: Mingqi Qiao qmingqi@163.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Public Mental Health, a section of the journal Frontiers in Public Health

Received: 18 August 2020 Accepted: 19 March 2021 Published: 21 April 2021

Citation:

Gao M, Gao D, Sun H, Cheng X, An L and Qiao M (2021) Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis. Front. Public Health 9:596128. doi: 10.3389/fpubh.2021.596128 **Background:** The global incidence of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) is increasing, with increasing suicide reports. However, the bibliometric analysis of global research on PMS and PMDD is rare. We aimed to evaluate the global scientific output of research on PMS and PMDD and to explore their research hotspots and frontiers from 1945 to 2018 using a bibliometric analysis methodology.

Methods: Articles with research on PMS and PMDD between 1945 and 2018 were retrieved from the Web of Science Core Collection (WoSCC). We used the bibliometric method, CiteSpace V and VOSviewer to analyze publication years, journals, countries, institutions, authors, research hotspots, and trends. We plotted the reference co-citation network, and we used keywords to analyze the research hotspots and trends.

Results: We identified 2,833 publications on PMS and PMDD research from 1945 to 2018, and the annual publication number increased with time, with fluctuations. Psychoneuroendocrinology published the highest number of articles. The USA ranked the highest among the countries with the most publications, and the leading institute was UNIV PENN. Keyword and reference analysis indicated that the menstrual cycle, depression and ovarian hormones were the research hotspots, whereas prevalence, systematic review, anxiety and depression and young women were the research frontiers.

Conclusions: We depicted overall research on PMS and PMDD by a bibliometric analysis methodology. Prevalence and impact in young women, systematic review evaluations of risk factors, and the association of anxiety and depression with menstrual cycle phases are the latest research frontiers that will pioneer the direction of research in the next few years.

Keywords: PMS/PMDD, CiteSpace, menstrual cycle, trend, bibliometric analysis

INTRODUCTION

Premenstrual syndrome (PMS), a common cyclical and recurrent disorder of the reproductive female population, is characterized by psychological and somatic symptoms that consistently occur during the luteal phase of the menstrual cycle (1). Women with more severe affective symptoms are classified as having premenstrual dysphoric disorder (PMDD), which is hereby designated as a depressive disorder in the DSM-5 (2, 3). Studies have shown that 75% of women of reproductive age are affected by disturbing premenstrual symptoms (4) and 5-8% of women thus suffer from severe PMS (2), and PMDD affects 3-8% of menstruating women (5). Diagnostic criteria for PMDD have been revised and updated, referring to newly discovered results from the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-4) (6) to the Diagnostic and Statistical Manual of Mental Disorders V (DSM-5) (7). In clinical diagnosis, the DSM-5 requires at least five specified symptoms for PMDD, while the ICD-10 requires only one distressing symptom for diagnosis of PMS (8).

Clinically, depression, anxiety, and irritability are seen as the three most studied symptoms of PMDD (9). And abdominal bloating, cramps or abdominal pain, irritability, and joint/muscle/back pains were the most prevalent symptoms in patients from France, Germany, Hungary, Italy, Spain, UK, Brazil, Mexico, Hong Kong, Pakistan, and Thailand (10). Recently, anger appears to be an important problem that makes life more difficult for subjects with PMDD (11). And there is a strong, independent association between PMS/PMDD and trait anger among a representative sample of female suicide attempters (12). Besides, recent evidence from studies indicates that sex steroids (progesterone, allopregnanolone, and estrogen) and central neurotransmitters (serotonin, gammaaminobutyric acid, glutamate and beta endorphins) maybe core mechanism (13-16). Psychological factors including perceived stress, tobacco consumption (17), neuroticism and coping strategies (negative cognitive styles) are strongly related to PMS/PMDD (18). It has been suggested that PMDD is a manifestation of the underlying depressive disorder which is associated with the inability to regulate emotions in an adaptive manner (19).

As research in PMS/PMDD advances rapidly, there still have been no attempts to systematically analyze the data on publications with so many scholarly papers published in journals in PMS/PMDD research over the past decade. Luckily, a bibliometric analysis methodology is widely used to assess trends in research activities as a quantitative analysis combining mathematical and statistical methods (20). Bibliometric analysis was utilized to detect the knowledge structure and emerging trends by quantitative analysis (21). In this study, CiteSpace (22) and VOSviewer (23) were applied to conduct a bibliometric analysis of related references derived from the Science Citation Index-Expanded (SCI-E) of the Web of Science database from 1945 to 2018. And this comprehensive bibliometric analysis that we will make aims to provide an overview of the status and to keep abreast of emerging trends and critical turns of the development of global research of PMS/PMDD.

METHODS

Data Source and Search Strategy

Literature retrieval was performed online through the SCI-E of the Web of Science Core Collection (WoSCC) on September 23, 2018. All searches were performed within the same day to avoid the bias caused by the daily database updates. The search queries are listed in **Table 1**.

Inclusion and Exclusion Criteria

Articles or reviews that met the following criteria were included: (1) articles published between 1945 and September 23, 2018; (2) articles indexed in the WoSCC; (3) articles on PMS/PMDD research, including original research and reviews; and (4) articles with basic information. The following documents were excluded: (1) meeting abstracts, proceedings, corrected articles, and repeated articles; (2) unpublished documents without enough information for further analysis; and (3) non-English publications. The screening and review strategy is illustrated in **Figure 1**.

Data Collection

Raw data from the WoSCC were initially downloaded and verified by two authors (Mingzhou Gao and Hui Sun) independently. The data were then imported into Excel 2019, VOSviewer and CiteSpace V and systematically analyzed.

Statistical Methods

A descriptive analysis was used to present the characteristics of the included studies by publication years, countries, journals, and authors. Then, we used CiteSpace V (version 5.3. R4) to construct knowledge maps. In addition, we also used VOSviewer software (version 1.6.9) for better network visualizations in some cases. Finally, we also applied burst detection to investigate the growth rate of citations or keywords with CiteSpace V.

RESULTS

Annual Publication Outputs

As showed in **Figure 2**, we counted the number of publications each year. Overall, there was an upward trend in publications from 1950 to 2008, but there were fluctuations in some years. However, we can see that the number of papers published in a single year reached a maximum of 124 in 2008. Then, there was a gradual downward trend from 2008 to 2018. Moreover, we can see that the trend in output was not stable; since 2000, there were fluctuations in 2001, 2007, 2009, 2012, 2016, and 2017. This finding may be due to the publication cycle. On the one hand, an upward trend indicates that PMS/PMDD research is becoming

Abbreviations: PMS, premenstrual syndrome; PMDD, premenstrual dysphoric disorder; WoSCC, Web of Science Core Collection; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

TABLE 1 | Search queries for premenstrual syndrome and premenstrual dysphoric disorder.

Mark	Number	Queries
# 1	3064	TS=(Premenstrual Syndrome) OR TS=(Premenstrual Syndromes) OR TS=(Syndrome, Premenstrual) OR TS=(Syndromes, Premenstrual) OR TS=(Premenstrual Tension) OR TS=(Premenstrual Tension) OR TS=(Tension, Premenstrual) OR TS=(Tensions, Premenstrual) Index =SCI-EXPANDED, CCR-EXPANDED, IC Time Span = All years
#2	1583	TS=(Premenstrual Dysphoric Disorder) OR TS=(Disorder, Premenstrual Dysphoric) OR TS=(Dysphoric Disorder, Premenstrual) OR TS=(Premenstrual Dysphoric Syndrome) OR TS=(Syndrome, Premenstrual Dysphoric) Index =SCI-EXPANDED, CCR-EXPANDED, IC Time Span = All years
#3	3852	#2 OR #1 Index =SCI-EXPANDED, CCR-EXPANDED, IC Time Span = All years
# 4	2833	#3 Refining basis: [Exclusion] Document type: (PROCEEDINGS PAPER OR NEWS ITEM OR REPRINT OR EDITORIAL MATERIAL OR CORRECTION OR ABSTRACT OF PUBLISHED ITEM OR MEETING ABSTRACT OR NOTE OR BOOK CHAPTER OR CORRECTION ADDITION OR LETTER OR BOOK REVIEW OR DISCUSSION) AND language: (ENGLISH) Time Span: all year. Index: SCI-EXPANDED, SSCI, CCR-EXPANDED, IC.



a hotspot, but a download trendency indicates that PMS/PMDD research attention tends to be flat.

Distribution of Journals and Co-cited Journals

In total, 295 academic journals have published articles on PMS/PMDD. According to the Journal Citation Reports (JCR) 2017 standards, the top 15 journals contributing to PMS/PMDD are shown in **Table 2**. Psychneuroendocrinology [impact factor (IF) 2017 = 4.731] published the most papers (79 publications, 2.789%), followed by the Journal of Psychosomatic Obstetrics and Gynecology (IF 2017 = 1.900, 61 publications; 2.153%), the

American Journal of Obstetrics and Gynecology (IF 2017 = 5.732, 50 publications; 1.765%) and Gynecological Endocrinology (IF 2017 = 1.453, 49 publications; 1.730%).

In addition, Biological Psychiatry (IF 2018 = 11.982) had an IF higher than 10, and Gynecology (IF 2018 = 5.732) had an IF between 10 and five. Five journals, Obstetrics and Gynecology (IF 2018 = 4.982), Psychoneuroendocrinology (IF 2018 = 4.731), the Journal of Clinical Psychiatry (IF 2018 = 4.247), Psychosomatic Medicine (IF 2018 = 3.810), and the Journal of Affective Disorders (IF 2018 = 3.786), had an IF between five and three.

We used CiteSpace's dual-map overlay function to construct a citation dual-map to visualize a more comprehensive view of



TABLE 2 | The top 15 journals with publications on PMS/PMDD research from 1945 to 2017.

Journal	Count	% of 2,833	IF 2017
Psychoneuroendocrinology	79	2.789	4.731
Journal of Psychosomatic Obstetrics and Gynecology	61	2.153	1.900
American Journal of Obstetrics and Gynecology	50	1.765	5.732
Gynecological Endocrinology	49	1.73	1.453
Journal of Affective Disorders	49	1.73	3.786
Obstetrics and Gynecology	47	1.659	4.982
Archives of Women's Mental Health	42	1.483	2.565
Journal of Reproductive Medicine	38	1.341	0.452
Journal of Women's Health	38	1.341	2.097
Journal of Psychosomatic Research	37	1.306	2.947
Journal of Clinical Psychiatry	35	1.235	4.247
Biological Psychiatry	31	1.094	11.982
Acta Obstetricia et Gynecologica Scandinavica	29	1.024	2.649
Psychosomatic Medicine	29	1.024	3.810

the citation state of PMS/PMDD. As showed in **Figure 3**, dualmap overlays could show the interactions of journals. And the left and right sides correspond to the citing and cited journal maps, respectively. The labels represent the disciplines covered by the journal. The lines on the map starting from the left and ending at the right represent the citation links.

There is eight citation paths in the dual-map overlays. The upward yellow path shows that papers published in immunology/biology journals mostly cited journals in the area of biology/genetics. The downward yellow path shows that papers published in immunology/biology journals mostly cited journals in education/social areas. The upward green path shows that papers published in medicine/medical/clinical journals mostly cited journals in the area of molecular biology/biology/genetics. The middle green path shows that papers published in medical/clinical journals partially cited journals in the health/nursing area. The bottom green path shows that papers published in medicine/medical/clinical journals partially cited journals in the psychology/education/social area. The upward blue path shows that papers published in psychology/education/health journals mostly cited journals in the molecular biology/biology/genetics area. The middle blue path shows that papers published in psychology/education/health journals partially cited journals in the health/nursing/medicine area. The bottom blue path shows that papers published in psychology/education/health journals partially cited journals in the psychology/education/health journals partially cited journals in the psychology/education/health journals partially cited journals in the psychology/education/social area (**Figure 3**).

Distribution of Countries/Regions and Institutes

The 2,833 publications on PMS/PMDD were contributed by 76 countries/regions. There was extensive collaboration between countries/regions (**Figure 4**). As showed in **Figure 4**, colors showed different research directions. The larger nodes represented the more influential countries in this field. In relation to the top 10 countries that contributed PMS/PMDD research, the USA had the largest number of publications (1242), pursued by England (274), Sweden (2267), and Canada (940) (**Table 3**). Among the top 10 countries/regions in PMS/PMDD research, there is two Asian countries, China and Japan. China is the sole country from the developing world to be in the top 10 countries that contributed PMS/PMDD research, showing its vast progress in life science over the past decade.

Over 1,700 institutions contributed to the publications on PMS/PMDD. Compared with countries, there was very little cooperation between the institutions (**Figure 5**). The lines between nodes represent the cooperative relationships among institutes. The length and thickness of the lines is the degree of cooperation among countries. The top 10 institutions contributed to 570 articles, which accounted for 20.12% of the total number of publications. The University of Pennsylvania







led the first research echelon, followed by the National Institute of Mental Health H, University of California, Los Angeles, Umea University, University of North Carolina, and Harvard University (**Table 3**).

Analysis of Author and Co-cited Author

More than 6,640 authors contributed to the total number of publications. The cooperation between authors is provided in a network map (**Figure 6**). The size of the nodes is equal to the number of citations. For authors who had the most publications, Backstrom T ranked the first (105 publications), followed by

TABLE 3 | The top 10 country/regions and institutions of PMS/PMDD research.

Rank	Country/region	Count	Institute	Count
1	USA	1,242	University of Pennsylvania	71
2	England	274	National Institute of Mental Health	70
3	Sweden	194	University of California, Los Angeles	70
4	Canada	174	Umea University	60
5	Australia	140	University of North Carolina	57
6	Italy	125	Harvard University	51
7	Germany	100	Yale University	51
8	Netherlands	77	McMaster University	49
9	Japan	74	University of California, San Diego	47
10	Peoples R China	62	Suny Buffalo	44

Rubinow DR (59 publications), Freeman EW (49 publications), and Schmidt PJ (45 publications) (**Figure 6** and **Table 3**).

Author citations tend to estimate the scientific relevance of publications. The top ranked author by citation count is Halbreich U (1978), with a citation count of 890. The second one is Steiner M (1980), with a citation count of 699. The third is **the American Psychiatric Association (1986), with a citation count of 616. The 4th is Freeman EW (1988), with a citation count of 603. The 5th is Rubinow DR (1985), with a citation count of 492. The 6th is Yonkers KA (1996), with a citation count of 491. The 7th is Endicott J (1984), with a citation count of 467. The 8th is Schmidt PJ (1992), with a citation count of 463. The 9th is Rapkin AJ (1990), with a citation count of 393 (**Table 4** and **Figure 7**).

Analysis of Co-cited References

We generated a cited reference co-citation map by selecting the top 10 articles per year and mapping them in 485 nodes and 241 links (**Figure 8**). An analysis in terms of co-citation counts (**Table 5** and **Figure 8**) revealed that the data on this topic over the past years were generally in the form of randomized trials, comparisons of diagnostic criteria (PSST) (28), pathogenesis (GABAA Receptor) and so on. For stance, Su et al. (24) performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with PMDD and they confirmed that fluoxetine is an effective treatment of PMDD with highest frequency. And pathogenesis was studied focusing on endogenous steroid, GABAA Receptor, progesterone, and gamma-aminobutyric acid (29–31).





TABLE 4 | The top 10 active authors with publications on PMS/PMDD research from 1995 to 2018.

Rank	Author	Count	Co-cited author	Count
1	Backstrom T	105	Halbreich U	890
2	Rubinow DR	59	Steiner M	699
3	Freeman EW	49	American Psychiatric Association	616
4	Schmidt PJ	45	Freeman EW	603
5	Halbreich U	43	Rubinow DR	492
6	Steiner M	42	Yonkers KA	491
7	Eriksson E	33	Endicott J	467
8	Nyberg S	32	Schmidt PJ	463
9	Girdler SS	31	Rapkin AJ	428
10	Yonkers KA	31	Backstrom T	393

Analysis of Co-occurring Keywords and Burst Terms

Over time, a knowledge map of keyword co-occurrence could reflect hot topics, and burst keywords (keywords that are cited frequently over a period of time) could indicate frontier topics. CiteSpace was utilized to construct a knowledge map of co-occurring keywords and identify the top 20 keywords in publications from 1945 to 2018 according to frequency, citation counts, and centrality (**Table 6**). Generating a keyword cooccurrence map resulted in 150 nodes and 842 links (**Figure 9**). Among the listed keywords, "premenstrual syndrome, menstrual cycle, premenstrual dysphoric disorder, women, symptom, luteal phase, depression, dysphoric disorder, premenstrual symptom, prevalence, double blind, progesterone, mood, oral contraceptive, and major depression" ranked ahead in both frequency and centrality, which suggested that they were the hotspots in the field. As we can see, "premenstrual syndrome and premenstrual dysphoric disorder" is ranked in the top three keywords, which is reasonable because they are our search terms. Except for them, other keywords actually reflect hotspots and topics that researchers are focusing on.

Research Hotspots and Topics of PMS/PMDD

Judging from the analysis of research hotspots, hot research topics revolve around the relationship of women's menstrual cycle with symptoms and progesterone. PMS/PMDD occurs only in women. According to the DSM-5, women with PMDD must have at least five predominantly affective symptoms with functional impairment, of which affective symptoms make up the largest proportion, such as mood swings, irritability, anger, and depressed mood. Therefore, the relationship between PMS/PMDD and the menstrual cycle has become a research



hotspot, many studies have explored this area (9, 32, 33). Besides, PMDD subtypes research represents one of the hotspots (34). For instance, Chinese scholars proved that liver-qi invasion syndrome and liver-qi depression syndrome are the major subtypes of PMS/PMDD with epidemiological research (35, 36). Regarding cyclic mood disorders, cognitive, sensory, and emotional changes are linked to the menstrual cycle. The reason for this association is the ovarian hormones, especially the hormones progesterone and estrogen (37). Progesterone and its metabolites (e.g., isoallopregnanolone) have been recognized as hot topics in scientific research on PMS/PMDD (13, 38). Most studies confirmed that PMDD pathophysiology is rooted in impaired GABAA-R response to dynamic ALLO fluctuations across the menstrual cycle, manifesting in affective symptoms and poor regulation of physiologic stress response (39-41).

Research Frontiers of PMS/PMDD

So-called "burst words" represent words that are cited frequently over a period of time. CiteSpace was used to detect burst keywords, which are deemed to be indicators of research frontier topics over time. In **Figure 10**, the time intervals are plotted on the green lines, while the periods of burst keywords are marked in red, indicating the beginning and end of the time interval of each burst. Among them, the keywords with citation bursts after 2008 were as follows: "prevalence" (2008– 2018), "systematic review" (2009–2018), "impact" (2011–2018), "dysmenorrhea" (2011–2018), "confidence interval" (2011–2018), "menstrual cycle phase" (2012–2018), "risk factor" (2013–2018), "anxiety" (2013–2018), "postpartum depression" (2013–2018), "premenstrual phase" (2014–2018), "dysphoric disorder" (2014–2018), "control group" (2015–2018), "quality of life" (2016–2018), and "young women" (2016–2018).

(1) Prevalence and impact in young women:

Currently, it is estimated that 3-8% of women of reproductive age meet the strict criteria for PMDD (42). The assessment of published reports demonstrated that the prevalence of clinically relevant PMS/PMDD is probably higher due to the strict diagnostic criteria. Although DSM-IV or DSM-5 are the main diagnostic criteria for PMDD, we found an interesting phenomenon in which researchers used a wide variety of diagnostic tools to identify the incidence of the disease in searching for cold-related literature. There continue to be many problems in the implementation of diagnostic criteria (43). For one, patients need to report bothersome premenstrual symptoms, and clinicians should become more proficient in the diagnostic process to prevent the under diagnosis of these disorders (44). Estimating the prevalence of PMS/PMDD in greater scope and depth in different countries/regions is becoming increasingly important. In further studies, we found that young women are becoming the center of research, such as women in the Ukraine (45), in universities in Jordan (46), and in Japanese colleges (47), Israeli students (19), and other students all over the world. On the one hand, research



TABLE 5	The top	10 co-cited	references	on	PMS/PMDD	durina	1945–2018.
IADEL 3	I THE LOP	TO CO-CILEU	1616161063	OU		uunng	1940-2010.

Rank	Freq	Author	Year	Source	Title
1	21	Steiner M (24)	1995	New Engl J Med	Fluoxetine in the Treatment of Premenstrual Dysphoria
2	19	Yonkers KA (2)	2008	Lancet	Premenstrual Syndrome
3	17	American Psychiatric Association (6)	1994	Diagn Stat Man Ment	Diagnostic and Statistical Manual of Mental Disorders (4th ed.)
4	9	Reid RL (25)	1981	Am J Obstet Gynecol	Premenstrual Syndrome
5	8	Steiner M (26)	1980	Acta Psychiat Scand	Treatment of Premenstrual Tension with Lithium Carbonate. A Pilot Study
6	7	Wittchen HU (27)	2002	Psychol Med	Prevalence, Incidence and Stability of Premenstrual Dysphoric Disorder in the Community.
7	5	Steiner M (28)	2003	Arch Womens Ment Health	The Premenstrual Symptoms Screening Tool (PSST) for Clinicians
8	5	Smith SS (29)	1998	Nature	GABAA Receptor $\alpha 4$ Subunit Suppression Prevents withdrawal Properties of ar Endogenous Steroid
9	5	Munday MR (30)	1981	Clin Endocrinol	Correlations between Progesterone, Estradiol and Aldosterone Levels in the Premenstrual Syndrome
10	5	Epperson CN (31)	2002	Arch Gen Psychiat	Cortical Gamma-aminobutyric Acid Levels across the Menstrual Cycle in Healthy Women and those with Premenstrual Dysphoric Disorder: a Proton Magnetic Resonance Spectroscopy Study

output on the prevalence and impact of PMS/PMDD is also increasing around the world, such as consequences on female students' behavior, cognitive abilities, mental health status, and academic performance (48) and the impact of symptoms on the quality of life (49). However, researchers have not yet fully grasped the prevalence of the disease, lacking systematic reviews on prevalence.

(2) Systematic Review evaluating risk factors:

Systematic reviews typically are about a detailed and comprehensive plan and search strategy derived *a priori*, with

TABLE 6 Top 20 keywords in terms of frequency and centrality in
PMS/PMDD research.

Ranking	Freq	Keyword	Centrality	Keyword
1	1556	Premenstrual syndrome	0.33	premenstrual syndrome
2	1024	Menstrual cycle	0.2	Symptom
3	845	Premenstrual dysphoric disorder	0.2	Premenstrual symptom
4	678	Women	0.14	Menstrual cycle
5	458	Symptom	0.12	Premenstrual dysphoric disorder
6	416	Luteal phase	0.12	Women
7	372	Depression	0.12	Dysphoric disorder
8	309	Dysphoric disorder	0.1	Luteal phase
9	306	Premenstrual symptom	0.1	Depression
10	276	Prevalence	0.08	Double blind
11	235	Double blind	0.08	Progesterone
12	223	Progesterone	0.06	Mood
13	193	Mood	0.06	Oral contraceptive
14	174	Oral contraceptive	0.06	Late luteal phase
15	162	Major depression	0.05	Prevalence
16	157	Follicular phase	0.05	Physical symptom
17	128	Estrogen	0.04	major depression
18	123	Significant difference	0.04	follicular phase
19	104	Late luteal phase	0.04	Estrogen
20	99	Controlled trial	0.04	Mood disorder

the goal of synthesizing findings qualitatively or quantitatively (50). Systematic reviews of randomized controlled trials are fundamental to the practice of evidence-based medicine and to evaluate the effectiveness of drugs and methods for the treatment of uncomfortable symptoms. For example, cognitive-behavioral therapy (43), herbs (51), and vitamins and minerals are employed in the treatment of premenstrual syndrome (52). A systematic review of acupuncture and acupressure showed improvements in both the physical and psychological symptoms of PMS when compared to a sham control (53). A systematic review of treatment pointed out the curative effect of herbal remedies for the treatment of PMS (51, 52).

(3) Association of anxiety and depression with menstrual cycle phases:

Menstrual-related mood disorders such as PMDD are mood disorders related to the menstrual cycle. As major symptoms of many emotional disorders, anxiety and depression are the key directions of research. Moreover, some studies regarded PMS/PMDD as a risk factor for postpartum depression (54–56). Symptoms of irritability, emotional hypersensitivity, increased anxiety and food cravings, sleep difficulties, and decreased concentration characterize PMDD as well as depression, particularly atypical depression. A lifetime history of depression ranges from \sim 20 to 76% in samples of women diagnosed with PMS or PMDD (57). Recent studies have shown that menopause and menstrual cycle phases are time of intense hormonal fluctuation that can cause increased vulnerability to depression and anxiety (58). Besides, neuroimaging indicated that the emotional distress and dysregulation related to PMDD



Dremenstrual syndrome1950normone1950ension syndrome1950ension syndrome1950ension syndrome1950ension1950ore menstrual tension1950bycle1950prolactin response1950orolactin response1950ohase dysphoric disorder1950ohase dysphoric disorder1950berimenstrual distress questionnaire1950uevere pm1950lisorder1950lisorder1950uoxetine1950oms symptom1950orogesterone1950orogesterone1950orogesterone1950oragesterone1950oragesterone1950oragesterone1950oragesterone1950orage depression1950orage depression1950ous dyschrider1950ous dyschrider1950ous cycle1950ous cycle1950our depression1950ous cycle1950our depression1950our depressio	4.2926 1991 22.6385 1991 5.5168 1991 4.9032 1991 13.9945 1991 21.9609 1992 8.3105 1992 8.3105 1992 4.4509 1993 16.5856 1993 20.927 1994 5.2654 1993 2.0927 1994 7.178 1996 6.0728 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.0506 3000 20.4544 2000	1991 1979 1998 1996 1996 1997 2002 1998 2002 1993 2002 1996 1998 1993 2002 1996 1993 2002 1993 2005 1995 2005 1997 2005 1997 2005 2005 2000	
premenstrual syndrome1950normone1950ension syndrome1950ension syndrome1950ension syndrome1950ore menstrual tension1950predection response1950prolactin response1950prolactin response1950phase dysphoric disorder1950hase dysphoric disorder1950evere pm1950evere pm1950evere pm1950menstrual distress questionnaire1950evere pm1950menstrual migraine1950mood1950oragesterone1950oragesterone1950orage terone1950progesterone1950progesterone1950progesterone1950progesterone1950progesterone1950progentick1950 <th>9.1308 1971 12.0011 1991 21.7656 1991 4.2926 1991 22.6385 1991 5.5168 1991 8.8574 1991 13.3945 1991 13.3945 1991 13.3945 1991 13.3945 1991 21.9609 1992 10.7443 1992 20.927 1994 13.296 1994 11.2391 1994 11.2391 1994 11.2391 1994 5.3819 1996 5.3819 1996 5.3819 1996 6.072 1996 6.978 1996 6.072 1996 6.07848 1998 10.3121 1998 12.5506 1999 22.5506 1999 20.5586 2000 20.4544 2000</th> <th>1979 1998 1998 1998 1998 1993 2002 1993 2002 1993 1993 1993 1993 1993 1995 1998 2005 1995 2005 1997 2000</th> <th></th>	9.1308 1971 12.0011 1991 21.7656 1991 4.2926 1991 22.6385 1991 5.5168 1991 8.8574 1991 13.3945 1991 13.3945 1991 13.3945 1991 13.3945 1991 21.9609 1992 10.7443 1992 20.927 1994 13.296 1994 11.2391 1994 11.2391 1994 11.2391 1994 5.3819 1996 5.3819 1996 5.3819 1996 6.072 1996 6.978 1996 6.072 1996 6.07848 1998 10.3121 1998 12.5506 1999 22.5506 1999 20.5586 2000 20.4544 2000	1979 1998 1998 1998 1998 1993 2002 1993 2002 1993 1993 1993 1993 1993 1995 1998 2005 1995 2005 1997 2000	
normone1950ension syndrome1950ension syndrome1950ension1950ension1950ore menstrual tension1950orolactin response1950ohase dysphoric disorder1950ohase dysphoric disorder1950ohase dysphoric disorder1950ohase dysphoric disorder1950ohase dysphoric disorder1950ohase dysphoric disorder1950ohase dysphoric disorder1950isorder1950isorder1950oms symptom1950oms symptom1950oncod1950ons symptom1950nood1950ons patient1950ostrogen1950ostrogen1950origo efforter1950origo efforter1950origo efforter1950origo efforter1950origo depression1950onoractive steroid1950onoractive steroid1950origonalone1950origonalone1950origo depression1950origonalone1950origonalone1950origonalone1950origonalone1950origo depression1950origo depression1950origo depression1950origo depression1950origo depression1950origo depression1950origo depression1950 <t< td=""><td>12.0011 1991 21.7656 1991 4.2926 1991 25.5168 1991 13.9945 1991 14.347 1991 14.347 1991 21.3609 1992 8.3105 1992 10.7443 1992 10.7443 1992 20.5543 1993 22.6543 1993 22.6543 1993 20.927 1994 7.7185 1996 5.3819 1994 7.7185 1996 5.3819 1996 6.6728 1996 6.6728 1996 6.072 1996 6.03648 1998 12.5506 1999 12.5506 1999 12.5506 1999 20.0568 2000 20.4544 2000</td><td>1998 1998 1996 1996 1993 2002 1993 2002 1993 1996 1998 1998 2005 1995 2005 1997 2000</td><td></td></t<>	12.0011 1991 21.7656 1991 4.2926 1991 25.5168 1991 13.9945 1991 14.347 1991 14.347 1991 21.3609 1992 8.3105 1992 10.7443 1992 10.7443 1992 20.5543 1993 22.6543 1993 22.6543 1993 20.927 1994 7.7185 1996 5.3819 1994 7.7185 1996 5.3819 1996 6.6728 1996 6.6728 1996 6.072 1996 6.03648 1998 12.5506 1999 12.5506 1999 12.5506 1999 20.0568 2000 20.4544 2000	1998 1998 1996 1996 1993 2002 1993 2002 1993 1996 1998 1998 2005 1995 2005 1997 2000	
ension syndrome 1950 iffective disorder 1950 ore menstrual tension 1950 ore menstrual tension 1950 ore menstrual tension 1950 ore menstrual tension 1950 ore menstrual symptom 1950 were particle and the symptom 1950 were tension 1950 menstrual distress questionnaire 1950 menstrual distress questionnaire 1950 menstrual distress questionnaire 1950 menstrual migraine 1950 orans patient 1950 oragesterone 1950 oragesterone 1950 oragesterone 1950 oragesterone 1950 oragesterone 1950 orage terone 1950 terotonin reuptake inhibitor 1950 orage terone 1950 orage controlled trial 1950 pidemology 1950 orage tradiol 1950 pidemology 1950 orage tradiol 1950 orage terone 1950 orage terone 1950 orage tradiol 1950 orage tradiol 1950 orage tradiol 1950 orage terone 1950 orage tradiol 1950 orage tradiol 1950 orage tradiol 1950 orage tradiol 1950 orage tradiol 1950 orage tradiol 1950 orage terone 1950 orage terone 1950 orage terone 1950 orage terone 1950 orage tradiol 1950 orage tradiol 1950 orage terone 1950	21.7656 1991 4.2926 1991 2.26385 1991 8.8574 1991 1.39945 1991 1.3945 1991 1.3945 1991 1.3945 1992 1.3609 1992 4.3105 1992 10.7443 1992 4.4509 1993 10.5856 1993 22.6543 1993 2.26543 1993 2.26543 1993 2.2926 1994 1.3291 1994 7.778 1994 7.778 1994 7.778 1994 7.778 1994 6.072 1996 6.072 1996 6.0788 1996 6.072 1996 6.0568 2000 20.4544 2000	1998 1996 1996 1993 2002 1993 1996 1998 1993 1993 1993 1993 1993 1993 1993 1993 1995 1995 2005 1997 2000	
affective disorder1950ension1950ore menstrual tension1950ore menstrual tension1950bacebo1950otacabo1950otacabo1	4.2926 1991 22.6385 1991 5.5168 1991 4.9032 1991 13.9945 1991 21.9609 1992 8.3105 1992 8.3105 1992 4.4509 1993 16.5856 1993 20.927 1994 5.2654 1993 2.0927 1994 7.178 1996 6.0728 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.0506 3000 20.4544 2000	1996 1996 1993 2002 1993 2002 1996 1997 1998 1999 1995 1995 1995 1995 1995 1995 2005 1997 2005 1997 2000	
ension1950ore menstrual tension1950ore menstrual tension1950orolactin response1950olacebo1950ohase dysphoric disorder1950onstrual distress questionnaire1950onserimenstrual symptom1950disorder1950uovetine1950onse symptom1950ons symptom1950menstrual migraine1950ons symptom1950menstrual migraine1950orogesterone1950orogesterone1950otat brain1950oractic disorder1950otat disorder1950otat brain1950orogesterone1950otat of sorder1950oractive steroid1950oractive steroid1950oractive steroid1950oractive steroid1950oractive steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oranotative steroid1950oractaceptive1950oractaceptive1950oractaceptive1950oracotraceptive1950oracotraceptive1950oracotraceptive1950oracotraceptive19	22.6385 1991 5.5168 1991 8.8574 1991 4.9032 1991 13.9945 1991 21.9609 1992 8.3105 1992 10.7443 1992 4.4509 1993 10.5856 1993 22.6543 1993 2.26543 1993 2.26543 1993 2.26543 1994 7.178 1994 7.178 1994 7.178 1994 5.3819 1996 6.072 1996 6.072 1996 6.072 1996 6.0548 1998 12.5506 1999 12.5506 1999 12.5506 1999 12.5506 1999	1996 1993 2002 1993 2002 1993 1996 1998 1995 1998 2005 1995 2005 2005 2005 2005 2000	
ner menstrual tension1950tycle1950prolactin response1950prolactin response1950placebo1950placebo1950placebo1950placebo1950menstrual distress questionnaire1950perimenstrual symptom1950uevere pm1950uevere pm1950uevere pm1950menstrual migraine1950mood1950orragesterone1950porgesterone1950portigesterone1950portigesterone1950portigesterone1950portigesterone1950portigesterone1950portigesterone1950portigesterone1950portige depression1950portige depression1950portige depression1950portige depression1950portige disorder1950portige anolone1950portige panolone1950patient disorder1950portige controlled trial1950portige controlled trial1950<	5.5168 1991 8.8574 1991 14.3032 1991 13.3945 1991 13.3945 1992 13.509 1992 8.3105 1992 10.7443 1992 10.7443 1992 10.5856 1993 12.56543 1993 10.5256 1994 7.778 1996 5.3819 1996 5.3819 1996 5.3819 1996 6.072 1996 6.072 1996 6.0788 1996 6.0788 1996 6.0788 1996 6.0568 1999 10.3121 1998 12.5506 1999 10.5526 1999 10.5526 1999 10.5526 1999	1993 2002 2002 2002 1996 1998 1993 1999 1995 2005 2005 2005 1997 2000	
sycle1950prolactbo1950placebo1950placebo1950ate luteal phase1950menstrual distress questionnaire1950menstrual symptom1950disorder1950disorder1950disorder1950menstrual migraine1950mood1950mood1950mood1950orgesterone1950eceptor1950at brain1950orgesterone1950at clisorder1950at clisorder1950orgesterone1950at clisorder1950orain1950o	8.8574 1991 4.9032 1991 13.9945 1991 14.347 1991 21.9609 1992 8.3105 1992 10.7443 1992 4.4509 1993 16.5856 1993 20.927 1994 5.296 1994 7.178 1996 5.3819 1994 7.7178 1994 7.7178 1994 7.7178 1994 6.072 1995 6.072 1996 6.0488 1998 10.3121 1998 12.5506 1999 12.5506 1999 20.9265 2000 20.4544 2000	2002 1993 2002 1996 1998 1993 1993 1995 1998 2005 2005 2005 1997 2000	
Proclactin response1950blacebo1950blacebo1950bate luteal phase1950brase dysphoric disorder1950benase dysphoric disorder1950benase dysphoric disorder1950luoxetine1950luoxetine1950luoxetine1950luoxetine1950menstrual migraine1950menstrual migraine1950mood1950orrogesterone1950eceptor1950eceptor1950eceptor1950strogen1950at brain1950eceptor1950eceptor1950eceptor1950at disorder1950elective serotonin reuptake inhibitor1950najor depression1950norodi disorder1950euroactive steroid1950eurosteroid1950otallopregnanolone1950eurosteroid1950paba(a) receptor1950endomized controlled trial1950oral contraceptive1950ordionized controlled trial1950ordionized controlled trial1950ordidence interval1950ordidence interval1950ordidence interval1950ordidence interval1950ordidence interval1950ordidence interval1950ordidence interval1950ordidence interval1950o	4.9032 1991 13.9945 1991 14.3471991 21.9609 1992 8.3105 1992 10.7443 1992 4.4509 1993 16.5856 1993 2.26543 1993 2.26543 1993 2.0927 1994 5.295 1994 7.178 1996 6.072 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.25506 1997 2.25506 1	1993 2002 1996 1998 1993 1999 1995 2005 1995 2005 1997 2000	
Alacebo1950ate luteal phase1950ate luteal phase1950menstrual distress questionnaire1950berimenstrual symptom1950lisorder1950lisorder1950luoxetine1950menstrual migraine1950mood1950oms symptom1950oms symptom1950oms patient1950at brain1950oragesterone1950oragesterone1950oati disorder1950oati disorder1950oati disorder1950oati disorder1950oati disorder1950oati disorder1950nage depression1950oati disorder1950oati contraceptive1950oati contraceptive1950oati contraceptive1950oati contraceptive1950oati contraceptive1950oati contraceptive1950obschenology1950obschenology1950obschenology1950oati contraceptive1950oati contraceptive1950oati contraceptive1950oati contr	13.9945 1991 14.347 1991 21.9609 1992 8.3105 1992 10.7443 1992 24.6504 1993 16.5856 1993 22.6543 1993 20.927 1994 4.3263 1993 20.927 1994 7.778 1994 7.778 1994 7.778 1996 5.3819 1996 6.978 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2002 1996 1998 1993 1999 1995 1995 2005 2005 1995 2005 2005 2000	
ate luteal phase1950phase dysphoric disorder1950perimenstrual symptom1950berimenstrual symptom1950lisorder1950lisorder1950licorder1950licorder1950licorder1950licorder1950licorder1950menstrual migraine1950at brain1950at brain1950at brain1950syster1950at brain1950at brain1950at collective serotonin reuptake inhibitor1950at collective serotonin reupt	14.347 1991 21.9609 1992 8.3105 1992 10.7443 1992 4.4509 1993 22.6543 1993 2.2.6543 1993 2.2.6543 1993 2.2.6543 1993 2.2.6543 1993 5.296 1994 7.178 1994 7.7785 1996 6.072 1996 6.072 1996 6.0488 1998 10.3121 1998 12.5506 1999 12.5506 1999 12.5506 1999 2.5506 1999	1996 1998 1993 1999 1995 2005 1998 2005 2005 1995 2005 1997 2000	
shase dysphoric disorder1950menstrual distress questionnaire1950severe pm1950lisorder1950lisorder1950borns symptom1950oms symptom1950menstrual migraine1950mood1950mood1950oms symptom1950mood1950mood1950orgesterone1950at brain1950strogen1950at concluster serotonin reuptake inhibitor1950orge depression1950najor depression1950navitety disorder1950opschaltric disorder1950najor depression1950opschaltric disorder1950opschaltric disorder1950opschaltric disorder1950strougenanolone1950opschaltric disorder1950strous cycle1950opschaltric disorder1950opschaltric disorder1950<	21.9609 1992 8.3105 1992 10.7443 1992 4.4509 1993 16.5856 1993 22.6543 1993 2.027 1994 5.296 1994 7.178 1996 6.072 1994 5.3819 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.05506 1990 2.04544 2000	1998 1993 1999 1995 2005 1995 2005 1995 2000	
menstrual distress questionnaire 1950 berimenstrual symptom 1950 lisorder 1950 lisorder 1950 menstrual migraine 1950 menstrual migraine 1950 mood 1950 oms patient 1950 orgesterone 1950 eceptor 1950 eceptor 1950 at brain 1950 orgesterone 1950 orgen depression 1950 orgen depression 1950 orgesterone 1950 orgen anolone 1950 orgen anolone 1950 orgen anolone 1950 orgen anolone 1950 orgen anolone 1950 orgesterone 1950	8.3105 1992 10.7443 1992 4.4509 1993 16.5856 1993 22.6543 1993 4.3263 1993 2.0.927 1994 5.296 1994 7.178 1996 7.7185 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 2.0.5506 1999 2.0.5506 3000 20.4544 2000	1993 1999 1995 2005 2005 2005 2005 2005 2000	
actimentual symptom1950levere pm1950lisorder1950lisorder1950lisorder1950linoterine1950menstrual migraine1950mood1950mood1950mood1950at brain1950cecptor1950setretee1950at brain1950cecptor1950at brain1950at brain1950at brain1950at cecptor1950at cecptor1950at cecptor1950at cecptor1950at cecptor1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banic disorder1950banonen replacement therapy1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barbanice1950barba	10.7443 1992 4.4509 1993 16.5856 1993 22.6543 1993 4.3263 1993 5.296 1994 11.2391 1994 7.778 1994 7.7785 1996 6.972 1996 6.972 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.5506 1990 20.4544 2000	1999 1995 2005 1998 2005 2005 1995 2005 2000	
avere pm1950disorder1950disorder1950huoxetine1950pms symptom1950menstrual migraine1950mood1950mood1950mood1950mood1950at brain1950orogesterone1950eceptor1950strogen1950at disorder1950eceptor1950at disorder1950elective serotonin reuptake inhibitor1950najor depression1950lobule blind1950navitety disorder1950oroner eplacement therapy1950oroner eplacement therapy1950pilopregnanolone1950oral contraceptive1950order spison1950dirospienone1950pistrous cycle1950order spison1950picade rat1950oral contraceptive1950orderspienone1950orderspienone1950orderspienone1950opstematual symptom1950opstematual symptom1950opstematual symptom1950opstematual symptom1950opstematual cycle phase1950opstematual symptom1950opstematual symptom1950opstematual symptom1950opstematual symptom1950opstematual symptom1950opstematual symptoric disorder1950	4.4509 1993 16.5856 1993 22.6543 1993 2.2.6543 1993 2.0.927 1994 5.296 1994 7.178 1994 7.178 1994 7.178 1996 6.072 1996 6.072 1996 6.0488 1998 10.3121 1998 12.5506 1999 12.5506 1999 2.0.568 2000 20.4544 2000	1995 1998 2005 1995 2005 1997 2000	
disorder1950luoxetine1950noms symptom1950nenotrual migraine1950nood1950oms patient1950at brain1950orrggesterone1950oard cisorder1950oard cisorder1950oard cisorder1950oard cisorder1950oardi cisorder1950oardi cisorder1950oardi cisorder1950namo depression1950oardi cisorder1950naurosteroid1950naurosteroid1950oardi cisorder1950naurosteroid1950naurosteroid1950naurosteroid1950naurosteroid1950naurosteroid1950naurosteroid1950naurosteroid1950naurosteroid1950paba(a) receptor1950andomized controlled trial1950pictaceptive1950pictaceptive1950pictaceptive1950pictaceptive1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950pictaceptic1950	16.5856 1993 22.6543 1993 4.3263 1993 5.296 1994 1.2391 1994 7.178 1994 7.7185 1996 6.072 1999 6.9188 1996 6.64648 1998 10.3121 1998 12.5506 1999 12.5506 1999 20.4544 2000	1998 2005 1995 2005 1997 2000	
luoxetine1950bms symptom1950merotonin1950menstrual migraine1950mood1950mood1950at brain1950orgesterone1950eceptor1950at at1950panic disorder1950ordiekterse1950at at1950panic disorder1950opanic disorder1950opanic disorder1950major depression1950at at1950opanic disorder1950opanic disorder1950opanic disorder1950opanic disorder1950opanole pression1950opanole pression1950opanole pression1950opanole disorder1950opanole disorder1950opanole disorder1950opanole appase1950opanole appase1950opanole appase1950opanole controlled trial1950opanole controlled trial1950opanole controlled trial1950opanole appasel women1950opanole appasel women1950opano	22.6543 1993 4.3263 1993 5.296 1994 5.296 1994 11.2391 1994 7.718 1994 7.7185 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 22.5506 1999 2.5506 1990 20.4544 2000	2005 1995 2005 1997 2000	
huxetine1950mms symptom1950menotinal migraine1950mood1950mood1950mood1950at brain1950progesterone1950eceptor1950at brain1950strogen1950panic disorder1950eceptor1950panic disorder1950panic disorder1950panic disorder1950panic disorder1950panic disorder1950panic disorder1950panic disorder1950panic disorder1950panixiety disorder1950panopause1950panopause1950panopause1950panopause1950panopause1950panopause1950panopause1950paral contraceptive1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950patradiol1950prospirenone1950patradiol1950patradiol1950patradiol1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone1950prospirenone </td <td>22.6543 1993 4.3263 1993 5.296 1994 5.296 1994 11.2391 1994 7.718 1994 7.7185 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 22.5506 1999 2.5506 1990 20.4544 2000</td> <td>2005 1995 2005 1997 2000</td> <td></td>	22.6543 1993 4.3263 1993 5.296 1994 5.296 1994 11.2391 1994 7.718 1994 7.7185 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 22.5506 1999 2.5506 1990 20.4544 2000	2005 1995 2005 1997 2000	
ms symptom1950nerotrual migraine1950neod1950nood1950nood1950orogesterone1950at brain1950serotrone1950at control (sorder1950at control (sorder1950orogesterone1950at control (sorder1950at control (sorder1950oranic disorder1950oranic disorder1950hajor depression1950hajor depression1950houble blind1950houble blind1950 <t< td=""><td>4.3263 1993 20.927 1994 5.296 1994 11.2391 1994 7.178 1994 5.3819 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 20.4564 2000 20.4544 2000</td><td>1995 2005 1997 2000</td><td></td></t<>	4.3263 1993 20.927 1994 5.296 1994 11.2391 1994 7.178 1994 5.3819 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 12.5506 1999 20.4564 2000 20.4544 2000	1995 2005 1997 2000	
erotonin1950menstrual migraine1950mood1950mood1950oms patient1950porggesterone1950eceptor1950patient1950porggesterone1950patient1950 <t< td=""><td>20.927 1994 5.296 1994 11.2391 1994 7.178 1994 7.7185 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000</td><td>2005 1997 2000</td><td></td></t<>	20.927 1994 5.296 1994 11.2391 1994 7.178 1994 7.7185 1996 6.072 1996 6.072 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2005 1997 2000	
menstrual migraine 1950 mood 1950 oms patient 1950 at brain 1950 eceptor 1950 eceptor 1950 at brain 1950 at brain 1950 at 1950 at 1950 at 1950 at 1950 at 1950 at 1950 eceptor 1950 at 1950 at 1950 eceptor 1950 etertorin reuptake inhibitor 1950 audic disorder 1950 audic blind 1950 etertorin reuptake inhibitor 1950 audic disorder 1950 invester disorder 1950 invester disorder 1950 invester disorder 1950 invester disorder 1950 invester disorder 1950 audic disorder 1950 invester disorder 1950 invester disorder 1950 inter disor	5.296 1994 11.2391 1994 7.718 1994 5.3819 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	1997 2000	
mood1950mms patient1950sms patient1950at brain1950progesterone1950eceptor1950strogen1950at1950at1950at1950progesterone1950at1950at1950product1950product1950najor depression1950houble blind1950naviety disorder1950proversteroid1950proversteroi	11.2391 1994 7.178 1994 7.7185 1996 5.3819 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2000	
nms patient1950at brain1950ar brain1950progesterone1950eceptor1950eceptor1950at1950at1950at1950eceptor1950at1950eceptor1950at1950eceptor1950eceptor1950belective serotonin reuptake inhibitor1950obuble blind1950euroactive steroid1950eurotonin reuptake inhibitor1950sychiatric disorder1950nenopause1950eurosteroid1950otamone replacement therapy1950jaba(a) receptor1950andomized controlled trial1950oral contraceptive1950orderaceptive1950pidemology1950ostrmenopausal women1950ostrmenopausal women1950ostrmenotrea1950ostrmenotrea1950ostrmenotrea1950ostrmenotrea1950ostrmenotrea1950 <td< td=""><td>7.178 1994 7.7185 1996 5.3819 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000</td><td>2000</td><td></td></td<>	7.178 1994 7.7185 1996 5.3819 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2000	
at brain1950progesterone1950eceptor1950eceptor1950at1950at1950at1950panic disorder1950peteroactive steroin reuptake inhibitor1950panic disorder1950peteroactive steroid1950peteroactive steroid1950peteroactive steroid1950peteroactive steroid1950peteroactive steroid1950peteroactive steroid1950peteroactive disorder1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950paba(a) receptor1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid1950peteroactorid <t< td=""><td>7.7185 1996 5.3819 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000</td><td>1000</td><td></td></t<>	7.7185 1996 5.3819 1996 6.072 1996 6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	1000	
progesterone1950eceptor1950eceptor1950strogen1950at1950panic disorder1950prain1950orain1950oute steroid1950hajor depression1950louble blind1950outiety disorder1950syschiatric disorder1950outretty disorder1950outretty disorder1950outpresteroid1950outpresteroid1950outpregnanolone1950emale rat1950andomized controlled trial1950dirospienone1950andomized controlled trial1950orderseptive1950orderseptive1950andomized controlled trial1950optomenopausal women1950optomenopausal women1950optomenopausal women1950optomenopausal women1950optomenopausal women1950optomenopausal women1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea1950optomenotrea </td <td>6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000</td> <td>2001</td> <td></td>	6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2001	
eceptor 1950 strogen 1950 at 1950 at 1950 at 1950 banic disorder 1950 real control reuptake inhibitor 1950 najor depression 1950 bouble blind 1950 terotonin reuptake inhibitor 1950 syschiatric disorder 1950 neurosteroid 1950 neurosteroid 1950 neurosteroid 1950 informen replacement therapy 1950 dilopregnanolone 1950 normone replacement therapy 1950 dilnical trial 1950 storus cycle 1950 oral contraceptive 1950 oral contraceptive 1950 oralodnized controlled trial 1950 pidemology 1950 oralodnized store 1950 store 1950 s	6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	1999	
estrogen 1950 at 1950 at 1950 anic disorder 1950 belective serotonin reuptake inhibitor 1950 belective serotonin reuptake inhibitor 1950 belective steroid 1950 bouble blind 1950 belective steroid 1950 bouble blind 1950 belective steroid 1950 belective disorder 1950 bele	6.9188 1996 6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2000	
at 1950 panic disorder 1950 panic disorder 1950 prain 1950 prain 1950 neuroactive steroid 1950 houble blind 1950 hourone replacement therapy 1950 clinical trial 1950 emale rat 1950 emale rat 1950 hormone replacement therapy 1950 emale rat 1950 houble discreptor 1950 houble trial 1950 houble discreptor 1950	6.6488 1998 10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000	2000	
banic disorder 1950 belective serotonin reuptake inhibitor 1950 rorain 1950 beuroactive steroid 1950 beuroactive steroid 1950 bouble blind 1950 beurotonin reuptake inhibitor 1950 beurotonin reuptake inhibitor 1950 beurotanin reuptake inhibitor 1950 beurotanin reuptake inhibitor 1950 beurotaroid 1950 beurotaroid 1950 beurotaroid 1950 beurotaroid 1950 beurotaroid 1950 beurotaroid 1950 beurotaroid 1950 berotaroid 1950 berotaroid 1950 beata	10.3121 1998 12.5506 1999 6.0568 2000 20.4544 2000		
elective serotonin reuptake inhibitor 1950 orain 1950 neuroactive steroid 1950 louble blind 1950 erotonin reuptake inhibitor 1950 erotonin reuptake inhibitor 1950 sochiatric disorder 1950 informane replacement therapy 1950 lilopregnanolone 1950 normone replacement therapy 1950 lilincal trial 1950 paba(a) receptor 1950 and ontized controlled trial 1950 oral contraceptive 1950 oral contraceptive 1950 oral contraceptive 1950 prespience 1950 prespience 1950 prespience 1950 oral contraceptive 1950 prespience 1950 prespience 1950 prespience 1950 prespience 1950 prespience 1950 prespience 1950 prespience 1950 prespience 1950 ortendel trial 1950 prespience 1950 ortendel trial 1950 prespience 1950 epidemiology 1950 prespience 1950 epidemiology 1950 prespience 1950 epidemiology 1950 optiming stradiol 1950 optimengausal women 1950 estradiol 1950 optimengausal women 1950 optimatic review 1950 optimengausal women 1950 optimatic review 1950 optim	12.5506 1999 6.0568 2000 20.4544 2000	2006	
brain 1950 beuroactive steroid 1950 heuroactive steroid 1950 houble blind 1950 bouble blind 1950 houble blind 1950 boucharic disorder 1950 boucharic disorder 1950 heurosteroid 1950 heurosteroid 1950 hormone replacement therapy 1950 clinical trial 1950 emale rat 1950 andomized controlled trial 1950 officacy 1950 totraceptive 1950 brond contraceptive 1950 andomized controlled trial 1950 officacy 1950 brond contraceptive 1950 brond controlled trial 1950 brond controlled controlled trial 1950 brond controlled controlled controlled cont	6.0568 2000 20.4544 2000		
neuroactive steroid 1950 major depression 1950 Jouble blind 1950 serotonin reuptake inhibitor 1950 serotonin reuptake inhibitor 1950 nuxiety disorder 1950 neurosteroid 1950 neurosteroid 1950 nenopause 1950 normone replacement therapy 1950 dilnical trial 1950 storus cycle 1950 gaba(a) receptor 1950 andomized controlled trial 1950 andomized controlled trial 1950 prevalence 1950 orevalence 1950 orevalence 1950 polacebo controlled trial 1950 pidemiology 1950 obterbased 1950 obterbased 1950 postmenopausal women 1950 ostrmenopausal women 1950 ostrmenopausal women 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 infigance 1950 oremenstrual difference 1950 oremenstrual difference 1950 nenstrual cycle phase 1950 oremenstrual phase 1950 omenstrual phase 1950 ost factor 1950 nenstrual phase 1950 isk factor 1950	20.4544 2000		
najor depression1950louble blind1950louble blind1950louble blind1950leorotonin reuptake inhibitor1950psychiatric disorder1950ballopregnanolone1950normene replacement therapy1950linical trial1950gaba(a) receptor1950andomized controlled trial1950oral contraceptive1950oral contraceptive1950oral contraceptive1950oral contraceptive1950oravalence1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950spatial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial1950optidet trial symptom1950optidence interval1950optidence interval1950optimenstrual dysphoric disorder1950ignificant difference1950main outcome measure1950main outcome measure1950opti1950isk factor1950			
Advible blind1950terotonin reuptake inhibitor1950nxiety disorder1950osychiatric disorder1950osychiatric disorder1950neurosteroid1950ulopregnanolone1950inoranone replacement therapy1950cinical trial1950emale rat1950ordinzaceptive1950andomized controlled trial1950ordincled trial1950dirospirenone1950ordinatic review1950ordintraceptive1950ordinatic review1950optimenopausal women1950optimenopausal women1950optimenopausal women1950optimenopausal women1950optimenorthea1950optimenopausal women1950optimenopausal women1950optimenopausal women1950optimenopausal women1950optimenopausal women1950optimenotrhea1950optimenotrhea1950optimenotrhea1950optimenotrhea1950optimentual dysphoric disorder1950optimenstrual cycle phase1950menstrual cycle phase1950main outcome measure1950menstrual phase1950optimentual phase1950optimentual phase1950optimentual phase1950optimentual phase1950optimentual phase1950optimentual phase195			
erotonin reuptake inhibitor 1950 inxitety disorder 1950 sychiatric disorder 1950 neurosteroid 1950 nenopause 1950 normone replacement therapy 1950 dilnical trial 1950 istrous cycle 1950 gaba(a) receptor 1950 andomized controlled trial 1950 andomized controlled trial 1950 oral contraceptive 1950 oral contraceptive 1950 oralocontraceptive 1950 pickenology 1950 pickenology 1950 obschence 1950 oravalence 1950 pickenology 1950 obschence 1950 pickenology 1950 obschence 1950 pickenology 1950 obschence 1950 pickenology 1950 obschence 1950 remenstrual symptom 1950 tritisy 1950 oramenstrual dysphoric disorder 1950 tress 1950 menstrual cycle phase 1950 menstrual phase 1950 isk factor 1950			
Inviety disorder1950sychiatric disorder1950sychiatric disorder1950neurosteroid1950allopregnanolone1950normene replacement therapy1950ilinical trial1950paba(a) receptor1950paba(a) receptor1950oral contraceptive1950oral contraceptive1950oral contraceptive1950oracontrolled trial1950orevalence1950optical trial1950optical trial1950optical trial1950optical trial1950optical trial1950optical trial1950optical trial1950spidemiology1950systematic review1950opticatiol<	9.808 2001	2003	
bychiatric disorder 1950 neurosteroid 1950 lilopregnanolone 1950 normone replacement therapy 1950 dinical trial 1950 sistrous cycle 1950 emale rat 1950 oral contraceptive 1950 andomized controlled trial 1950 drospirenone 1950 orevalence 1950 orevalence 1950 sontrolled trial 1950 sontrolled trial 1950 bit sistro 1950 postmenopausal women 1950 ostmenopausal women 1950 ostmenopausal women 1950 ostmenopausal women 1950 ostmenopausal women 1950 ostmenopausal women 1950 ostmenopausal women 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptom 1950 oremenstrual symptor 1950 oremenstrual sympt	10.461 2001	2004	
reverse for the second	8.4526 2002	2006	
Illopregnanolone1950menopause1950normone replacement therapy1950clinical trial1950strous cycle1950gaba(a) receptor1950andomized controlled trial1950andomized controlled trial1950orevalence1950ortacoptive1950ortacoptive1950ortacoptive1950orevalence1950optical trial1950optical trial trial trial trial1950optical trial tria	4.9955 2002	2009	
menopause1950normone replacement therapy1950normone replacement therapy1950inical trial1950estrous cycle1950gaba(a) receptor1950oral contraceptive1950oral contraceptive1950orospirenone1950orospirenone1950othrouge trial1950othrouge trial195	18.6683 2003	2007	
normone replacement therapy1950linical trial1950strous cycle1950paba(a) receptor1950gaba(a) receptor1950andomized controlled trial1950andomized controlled trial1950prevalence1950pidemiology1950pidemiology1950pidemiology1950pidemiology1950pidemiology1950postmenopausal women1950postmenorhea1950postmenopausal women1950postmenorhea1950postmenorhea1950postmenorhea1950postmenorhea1950postmenorhea1950postmenorhea1950postmentrea <td>22.11 2003</td> <td>2007</td> <td></td>	22.11 2003	2007	
normone replacement therapy1950ilinical trial1950istrous cycle1950gaba(a) receptor1950gaba(a) receptor1950andomized controlled trial1950andomized controlled trial1950provalence1950ordicontraceptive1950ordicontraceptive1950ordicontraceptive1950ordical trial1950ordical trial1950obscience1950obscience1950obscience1950obscience1950obscience1950ostradiol1950ostradiol1950oremenstrual symptom1950oremenstrual dysphoric disorder1950oremenstrual dysphoric disorder1950otress1950otress1950onfidence interval1950inginficant difference1950menstrual cycle phase1950menstrual phase1950om1950om1950om1950om1950om1950optical trial1950optical trial19	8.5836 2003	2004	
dinical trial1950strous cycle1950paba(a) receptor1950emale rat1950andomized controlled trial1950dinomized controlled trial1950prospirenone1950prospirenone1950prostemology1950controlled trial1950prospirenone1950prostemology1950prostemology1950postemology1950postemology1950postemology1950postemology1950postemology1950postemology1950postemology1950postemology1950postemology1950postenatic review1950postenatic review1950postenatic review1950postenatic review1950postenatic1950postenatic1950postenatic1950postenatic1950postenatic1950postenatical dysphoric disorder1950menstrual cycle phase1950main outcome measure1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post1950post <td></td> <td></td> <td></td>			
estrous cycle 1950 gaba(a) receptor 1950 emale rat 1950 oral contraceptive 1950 drospirenone 1950 orospirenone 1950 orospirenone 1950 orospirenone 1950 orotrolled trial 1950 other 1950 oth		and a second	
gaba(a) receptor1950emale rat1950oral contraceptive1950andomized controlled trial1950prospienone1950orevalence1950orevalence1950pidemiology1950olacebo controlled trial1950obscher1950obscher1950obscher1950obscher1950obscher1950obscher1950obscher1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950oremenstrual symptom1950onfidence interval1950orgenenstrual dysphoric disorder1950otress1950orgenenstrual difference1950menstrual cycle phase1950menstrual phase1950om1950om1950om1950om1950oremenstrual phase1950om <td>8.035 2005</td> <td></td> <td></td>	8.035 2005		
emale rat 1950 oral contraceptive 1950 andomized controlled trial 1950 drospirenone 1950 drospirenone 1950 orevalence 1950 orevalence 1950 postematic drial 1950 polacebo controlled trial 1950 polacebo controlled trial 1950 systematic review 1950 opstematic all 1950 opstematic interval 1950 tignificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 optimenstrual phase 1950 isk factor 1950			
pral contraceptive1950andomized controlled trial1950drospirenone1950prevalence1950prevalence1950controlled trial1950controlled trial1950pidemiology1950pidemiology1950systematic review1950pestradiol1950prevalence1950prevalence1950prevalence1950prevalence1950prevalence1950prevalence1950prevalence1950prevalence1950prevalence1950confidence interval1950ordermenstrual dysphoric disorder1950iginificant difference1950menstrual cycle phase1950main outcome measure1950prevalence1950 <td></td> <td></td> <td></td>			
andomized controlled trial1950drospirenone1950orevalence1950officacy1950controlled trial1950pidemiology1950olacebo controlled trial1950obstradiol1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950ostmenopausal women1950nealth1950oremenstrual symptom1950oremenstrual dysphoric disorder1950otress1950ignificant difference1950menstrual cycle phase1950menstrual phase1950om1950om1950	14.6988 2007		
drospirenone1950orevalence1950orevalence1950orevalence1950orontrolled trial1950oplacebo controlled trial1950obacebo controlled trial1950oplacebo controlled trial1950systematic review1950opstemopausal women1950oremenstrual symptom1950opmact1950opstemorrhea1950diagnosis1950oremenstrual dysphoric disorder1950orignificant difference1950main outcome measure1950main outcome measure1950om1950main systematic review1950menstrual phase1950om1950main systematic review1950menstrual cycle phase1950menstrual phase1950om1950main systematic review1950menstrual phase1950main systematic review1950main systematic review1950systematic review1950systematic review1950systematic review1950systematic review1950systematic review1950systematic review1950sy			
brevalence 1950 prificacy 1950 controlled trial 1950 poldemiology 1950 placebo controlled trial 1950 thinyl estradiol 1950 postmenopausal women 1950 pertadiol 1950 pertadiol 1950 pertadiol 1950 pertadiol 1950 pertadiol 1950 pertadiol 1950 promenstrual symptom 1950 confidence interval 1950 pormenstrual dysphoric disorder 1950 promenstrual cycle phase 1950 menstrual cycle phase 1950 menstrual phase 1950 por 1950 pertadiol 19			
efficacy1950controlled trial1950controlled trial1950pidemiology1950placebo controlled trial1950psthinyl estradiol1950postmenopausal women1950pstradiol1950premenstrual symptom1950macht1950postmenopausal women1950premenstrual symptom1950macht1950confidence interval1950premenstrual dysphoric disorder1950ignificant difference1950menstrual cycle phase1950main outcome measure1950pm19	20 7052 2008	2010	
controlled trial1950spidemiology1950placebo controlled trial1950obacebo controlled trial1950ethinyl estradiol1950opstmenopausal women1950opstradiol1950opstradiol1950opstradiol1950opstradiol1950opstradiol1950dysmenorrhea1950diagnosis1950oremenstrual dysphoric disorder1950rignificant difference1950main outcome measure1950main outcome measure1950om1950om1950sk factor1950			
epidemiology 1950 slacebo controlled trial 1950 tithinyl estradiol 1950 systematic review 1950 systematic review 1950 ostmenopausal women 1950 restradiol 1950 opremenstrual symptom 1950 yasmenorhea 1950 diagnosis 1950 sonfidence interval 1950 onfidence interval 1950 inginificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 om 1950 som			
blacebo controlled trial 1950 trhinyl estradiol 1950 ystematic review 1950 postmenopausal women 1950 postmenopausal women 1950 postmenopausal women 1950 nealth 1950 mpact 1950 diagnosis 1950 oremenstrual dysphoric disorder 1950 oremenstrual dysphoric disorder 1950 neenstrual cycle phase 1950 menstrual phase 1950 menstrual phase 1950 pm 1950 isk factor 1950	8.9442 2008	2009	
ethinyl estradiol1950systematic review1950oostmenopausal women1950ostradiol1950stradiol1950mealth1950dysmenorrhea1950dysmenorrhea1950diagnosis1950oremenstrual dysphoric disorder1950ignificant difference1950main outcome measure1950main outcome measure1950om1950sign factor1950nenstrual cycle phase1950menstrual phase1950om1950sign factor1950			
ystematic review 1950 postmenopausal women 1950 setradiol 1950 premenstrual symptom 1950 mealth 1950 hysmenorrhea 1950 josmfidence interval 1950 oremenstrual dysphoric disorder 1950 oremenstrual cycle phase 1950 menstrual cycle phase 1950 menstrual phase 1950			
Jost postmenopausal women1950staradiol1950stradiol1950premenstrual symptom1950mach1950ysmenorrhea1950confidence interval1950diagnosis1950oremenstrual dysphoric disorder1950ignificant difference1950meinstrual cycle phase1950main outcome measure1950om1950om1950	11.084 2008	2009	
estradiol 1950 premenstrual symptom 1950 neealth 1950 mpact 1950 dysmenorrhea 1950 dysmenorrhea 1950 idiginosis 1950 premenstrual dysphoric disorder 1950 nignificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 om 1950			
oremenstrual symptom 1950 nealth 1950 mpact 1950 dysmenorrhea 1950 dysmenorrhea 1950 diagnosis 1950 oremenstrual dysphoric disorder 1950 nignificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 isk factor 1950			
health 1950 mpact 1950 ysmenorrhea 1950 tonfidence interval 1950 idiagnosis 1950 oremenstrual dysphoric disorder 1950 ittress 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 om 1950 isk factor 1950			
mpact1950tysmenorrhea1950confidence interval1950idiagnosis1950orremenstrual dysphoric disorder1950idignificant difference1950menstrual cycle phase1950menstrual phase1950om1950isk factor1950	6.9873 2010	2012	
dysmenorrhea 1950 confidence interval 1950 diagnosis 1950 oremenstrual dysphoric disorder 1950 ignificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 om 1950	8.2607 2010	2014	
dysmenorrhea 1950 confidence interval 1950 diagnosis 1950 oremenstrual dysphoric disorder 1950 ignificant difference 1950 menstrual cycle phase 1950 menstrual phase 1950 om 1950 om 1950			
onfidence interval1950ilagnosis1950oremenstrual dysphoric disorder1950ignificant difference1950menstrual cycle phase1950main outcome measure1950om1950om1950isk factor1950	10.0004 2011	2018	
diagnosis1950oremenstrual dysphoric disorder1950itress1950ignificant difference1950menstrual cycle phase1950menstrual phase1950menstrual phase1950om1950sk factor1950	5.8562 2011	2018	
tress 1950 ignificant difference 1950 menstrual cycle phase 1950 main outcome measure 1950 menstrual phase 1950 pm 1950 isk factor 1950	9.8495 2011	2014	
tress 1950 ignificant difference 1950 menstrual cycle phase 1950 main outcome measure 1950 menstrual phase 1950 pm 1950 isk factor 1950	8.2728 2011	2015	
ignificant difference 1950 menstrual cycle phase 1950 main outcome measure 1950 menstrual phase 1950 om 1950 isk factor 1950			
nenstrual phase 1950 pm 1950 isk factor 1950	5.4789 2012	2013	
nenstrual phase 1950 pm 1950 isk factor 1950	15.2126 2012	2018	
nenstrual phase 1950 pm 1950 isk factor 1950	5 5882 2012	2016	
om 1950 isk factor 1950 inxiety 1950	6.0912 2012	2016	
isk factor 1950 Inxiety 1950	12 1205 2012	2016	
ляктастог 1950 Inxiety 1950	13.1395 2012	2015	
inxiety 1950	13.5293 2013	2018	
and the second	6.4609 2013	2018	
postpartum depression 1950	6.2761 2013	2018	
depressive symptom 1950	6.6465 2013	2016	
nealthy women 1950	6.5264 2013	2015	
premenstrual phase 1950	6.5451 2014	2018	
dysphoric disorder 1950	14.4731 2014	2018	
ex difference 1950		2015	
nood disorder 1950	9.3254 2014	2015	
physical symptom 1950	9.3254 2014 7.5269 2014	2016	
control group 1950	9.3254 2014 7.5269 2014 8.4026 2015	2018	
association 1950	7.5269 2014 8.4026 2015 10.682 2015	2018	
quality of life 1950	7.5269 2014 8.4026 2015 10.682 2015	2018	
voung women 1950	7.5269 2014 8.4026 2015 10.682 2015	2018	

FIGURE 10 | Top 84 keywords with the strongest citation bursts.

seem to be determined by structural, chemical, and functional brain signatures (59).

DISCUSSION

In this study, we have formulated research strategies to comprehensively analyze the current situation and development trend of PMDD research from 1945 to 2018 using a bibliometric analysis methodology. And we collected 2,833 papers for bibliographic records after evaluating 3,852 original results from the search for PMS/PMDD-related papers published in the Web of Science from 1945 to 2018 on the basis of the inclusion and exclusion criteria. Publications about PMS/PMDD could go back to 1950. In 1950, three articles were published: "Nephrotic syndrome with exaggerated premenstrual water and salt retention," written by Lippman (60); "Premenstrual tension," written by Morton (61), who worked at the New York Medical College; and "Premenstrual tension treated with vitamin A," written by Argonz and Abinzano (62). Since then, PMDD research has gradually developed.

Our finding indicated that PMS/PMDD research is currently an area of active investigation and numerous findings are constantly emerging. Journals related to gynecology and endocrinology published most of PMS/PMDD research, such as Psychneuroendocrinology and Journal of Psychosomatic Obstetrics and Gynecology. USA had the largest number of publications, but China was the only country from the developing world to be in the top 10 countries that contributed PMS/PMDD research, showing its vast progress in life science over the past decade. And Research institutions were mainly in the USA (University of Rochester). Backstrom T ranked the first in more than 6,640 authors who contributed to the total number of publications, but Halbreich U leads the research direction.

In addition, we also find out the hotspots and trend of PMS/PMDD research through co-occurring keywords and burst terms, as described above. Prevalence and impact in young women, systematic review evaluating risk factors and association of anxiety and depression with menstrual cycle phases are research frontiers of PMS/PMDD. These forecasts have been confirmed in 2020–2021, such as research in Japanese college students (63) and systematic review on addictive behaviors across the menstrual cycle (64). But there are limitations in our research. Due to the large time span of submission of research papers, the statistical data of this paper is up to 2018. Even so, this study is enough to reflect the research hot spots and trends from 1945 to 2018.

REFERENCES

- 1. Dalton K. What is this PMS? J R Coll Gen Pract. (1982) 32:717-23.
- Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. (2008) 371:1200–10. doi: 10.1016/S0140-6736(08)60527-9
- Hantsoo L, Epperson CN. Premenstrual dysphoric disorder: epidemiology and treatment. *Curr Psychiatry Rep.* (2015) 17:87. doi: 10.1007/s11920-015-0628-3

CONCLUSION

To the best of our understanding, this paper is the first bibliometric analysis of trends in PMS/PMDD research over the past decade. The data analysis process was relatively unbiased. The number of publications in PMS/PMDD research has been growing over the past decade. The USA, ENGLAND and SWEDEN were the top three countries contributing to PMS/PMDD studies. There was active collaboration between developed countries. China was the sole developing country that made it into the list of the top ten countries contributing to PMS/PMDD studies. The USA and its institutions still occupy the leading position. UNIV PENN, the NIMH, and UNIV CALIF LOS ANGELES may be ideal candidates for academic cooperation. Prevalence and impact in young women, systematic review evaluations of risk factors, and the association of anxiety and depression with menstrual cycle phases may be frontiers in this field, and researchers should follow closely relevant studies in the coming years.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

MG conceived and designed the studies and drafted the manuscript. MG, HS, and DG performed the experiments, analyzed the data, contributed materials/analysis tools, prepared figures and/or tables, and approved the final draft. XC, LA, and MQ provide critical services. Fund support was supplied by DG and MQ. All authors read and approved the final manuscript.

FUNDING

This work was supported by National Science & Technology Major Project Key New Drug Creation and Manufacturing Program of China (SQ2017ZX091064) and National Natural Science Foundation of China (81001484 and 81473558).

ACKNOWLEDGMENTS

The authors would like to thank the editor and reviewers for their contributions to improving the quality of this paper.

- Kues JN, Janda C, Kleinstauber M, Weise C. How to measure the impact of premenstrual symptoms? Development and validation of the German PMS-Impact Questionnaire. Women Health. (2016) 56:807–26. doi: 10.1080/03630242.2015.1118734
- Rapkin AJ, Lewis EI. Treatment of premenstrual dysphoric disorder. Womens Health. (2013) 9:537–56.
- 6. Hennes JL, Rodes M. *Diagnostic and Statistical Manual of Mental Disorders*. American Psychiatric Association (1994).

- 7. APA. *Mood Disorders in the DSM-5.* 5th ed. Arlington, VA: American Psychiatric Publishing (2013).
- Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. *Psychoneuroendocrinology*. (2003) 28(Suppl. 3):25– 37. doi: 10.1016/S0306-4530(03)00099-4
- Ko CH, Long CY, Chen SY, Chen IJ, Huang TH, Yen JY. Depression, irritability, and anxiety in women with premenstrual dysphoric disorder. *Int J Psychiatry Med.* (2013) 46:39–55. doi: 10.2190/PM.46.1.d
- Dennerstein L, Lehert P, Heinemann K. Global study of women's experiences of premenstrual symptoms and their effects on daily life. *Menopause Int.* (2011) 17:88–95. doi: 10.1258/mi.2011.011027
- Soyda Akyol E, Karakaya Arisoy EO, Caykoylu A. Anger in women with premenstrual dysphoric disorder: its relations with premenstrual dysphoric disorder and sociodemographic and clinical variables. *Compr Psychiatry*. (2013) 54:850–5. doi: 10.1016/j.comppsych.2013.03.013
- Ducasse D, Jaussent I, Olié E, Guillaume S, Lopez-Castroman J, Courtet P. Personality traits of suicidality are associated with premenstrual syndrome and premenstrual dysphoric disorder in a suicidal women sample. *PLoS ONE*. (2016) 11:e0148653. doi: 10.1371/journal.pone.0148653
- Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M, et al. Allopregnanolone concentrations and premenstrual syndrome. *Eur J Endocrinol.* (2000) 142:269–73. doi: 10.1530/eje.0.1420269
- Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. (1998) 338:209–16. doi: 10.1056/NEJM199801223380401
- Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. *BMJ*. (2001) 323:776–80. doi: 10.1136/bmj.323.7316.776
- Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. *Psychopharmacology*. (2006) 186:323–33. doi: 10.1007/s00213-005-0168-3
- Fernandez MDM, Montes-Martinez A, Pineiro-Lamas M, Regueira-Mendez C, Takkouche B. Tobacco consumption and premenstrual syndrome: a case-control study. *PLoS ONE*. (2019) 14:e0218794. doi: 10.1371/journal.pone.0218794
- Del Mar Fernandez M, Regueira-Mendez C, Takkouche B. Psychological factors and premenstrual syndrome: a Spanish case-control study. *PLoS ONE*. (2019) 14:e0212557. doi: 10.1371/journal.pone.0212557
- Reuveni I, Rotem D, Ronen S, Ron E, Sofia L, Gadi G, et al. Emotional regulation difficulties and premenstrual symptoms among Israeli students. *Arch Womens Mental Health.* (2016) 19:1–8. doi: 10.1007/s00737-016-0663-z
- Tugce GA, Waaijer CJF, Magnus P. Scientific workflows for bibliometrics. Scientometrics. (2016) 107:385–98. doi: 10.1007/s11192-016-1885-6
- Luukkonen T. Bibliometrics and evaluation of research performance. Ann Med. (1990) 22:145–50. doi: 10.3109/07853899009147259
- Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inform Sci Technol. (2006) 57:359–77.
- van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics*. (2010) 84:523–58. doi: 10.1007/s11192-009-0146-3
- Su TP, Schmidt PJ, Danaceau MA, Tobin MB, Rosenstein DL, Murphy DL, et al. Fluoxetine in the treatment of premenstrual dysphoria. *N Engl J Med.* (1995) 332:1529–34.
- Reid RL, Yen SS. Premenstrual syndrome. Am J Obstetrics Gynecol. (1981) 139:85–104. doi: 10.1016/0002-9378(81)90417-8
- Steiner M, Haskett RF, Osmun JN, Carroll BJ. Treatment of premenstrual tension with lithium carbonate. A pilot study. *Acta Psychiatrica Scand.* (1980) 61:96–102. doi: 10.1111/j.1600-0447.1980.tb00569.x
- Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. *Psychol Med.* (2002) 32:119. doi: 10.1017/S0033291701004925
- Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women's Mental Health. (2003) 6:203–9. doi: 10.1007/s00737-003-0018-4
- Smith SS, Gong QH, Hsu FC, Markowitz RS, Ffrenchmullen JMH, Li X. GABAA receptor α4 subunit suppression prevents withdrawal properties

of an endogenous steroid. Nature. (1998) 392:926-30. doi: 10.1038/31948

- Munday MR, Brush MG, Taylor RW. Correlations between progesterone, oestradiol and aldosterone levels in the premenstrual syndrome. *Clin Endocrinol.* (1981) 14:1–9. doi: 10.1111/j.1365-2265.1981.tb00359.x
- Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. *Arch General Psychiatry.* (2002) 59:851–8. doi: 10.1001/archpsyc.59.9.851
- Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. *Acta Psychiatr Scand*. (2001) 104:110– 6. doi: 10.1034/j.1600-0447.2001.00412.x
- Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. (2005) 85:275–82. doi: 10.1016/j.jad.2004.10.004
- 34. Eisenlohr-Moul TA, Kaiser G, Weise C, Schmalenberger KM, Kiesner J, Ditzen B, et al. Are there temporal subtypes of premenstrual dysphoric disorder?: using group-based trajectory modeling to identify individual differences in symptom change. *Psychol Med.* (2019) 50:964–972. doi: 10.1017/S0033291719000849
- Qiao M, Zhang Z, Xu X, Han X, Yuzhen C, Qing Y. Epidemiological survey on syndromes distribution in PMS. *J Basic Med Traditional Chin Med.* (1997) 3:31–3.
- 36. Qiao M, Sun P, Wang H, Wang Y, Zhan X, Liu H, et al. Epidemiological distribution and subtype analysis of premenstrual dysphoric disorder syndromes and symptoms based on TCM theories. *Biomed Res Int.* (2017) 9:4595016. doi: 10.1155/2017/4595016
- Farage MA, Osborn TW, Maclean AB. Cognitive, sensory, and emotional changes associated with the menstrual cycle: a review. *Arch Gynecol Obstetrics*. (2008) 278:299–307. doi: 10.1007/s00404-008-0708-2
- Rapkin J, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. *Obstetrics Gynecol.* (1997) 90:709–14. doi: 10.1016/S0029-7844(97)00417-1
- Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. *Neurobiol Stress*. (2020) 12:100213. doi: 10.1016/j.ynstr.2020.100213
- Timby E, Bäckström TR, Nyberg S, Stenlund H, Wihlbäck ACN, Bixo M. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study. *Psychopharmacology.* (2016) 233:2109–17. doi: 10.1007/s00213-016-4258-1
- Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. Allopregnanolone and mood disorders. *Progress Neurobiol.* (2014) 113:88–94. doi: 10.1016/j.pneurobio.2013. 07.005
- Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). *Psychoneuroendocrinology*. (2003) 28(Suppl. 3):1–23. doi: 10.1016/S0306-4530(03)00098-2
- 43. Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. *Gynecol Endocrinol.* (2007) 23:123. doi: 10.1080/09513590601167969
- Futterman A. Advances in the diagnosis of premenstrual syndrome and premenstrual dysphoric disorder. *Expert Opin Med Diagnostics*. (2010) 4:91–8. doi: 10.1517/17530050903431418
- Crow EM, Jeannot E. Premenstrual syndrome: symptomatic and diagnosed prevalence, dualistic treatment approach – a cross-sectional study in Ukraine. *Int J Prev Med.* (2017) 8:66. doi: 10.4103/ijpvm.IJPVM_18_16
- Hussein SJ, Hamdanmansour AM. Prevalence and association of premenstrual syndrome and premenstrual dysphoric disorder with academic performance among female university students. *Perspect Psychiatric Care*. (2017) 54:1–9.
- 47. Takeda T, Imoto Y, Nagasawa H, Takeshita A, Shiina M. Fish consumption and premenstrual syndrome and dysphoric disorder in Japanese

Gao et al

collegiate athletes. J Pediatric Adolescent Gynecol. (2016) 29:386–9. doi: 10.1016/j.jpag.2016.01.122

- Hussein Shehadeh J, Hamdan-Mansour AM. Prevalence and association of premenstrual syndrome and premenstrual dysphoric disorder with academic performance among female university students. *Perspect Psychiatr Care*. (2018) 54:176–84. doi: 10.1111/ppc.12219
- Czajkowska M, Drosdzol-Cop A, Galazka I, Naworska B, Skrzypulec-Plinta V. Menstrual cycle and the prevalence of premenstrual syndrome/premenstrual dysphoric disorder in adolescent athletes. J Pediatr Adolesc Gynecol. (2015) 28:492–8. doi: 10.1016/j.jpag.2015.02.113
- Anderson WG, McNamara MC, Arnold RM. Systematic reviews and metaanalyses. J Palliat Med. (2009) 12:937–46. doi: 10.1089/jpm.2009.9954
- Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosomatic Obstetrics Gynaecol. (2011) 32:42. doi: 10.3109/0167482X.2010.538102
- 52. Whelan M, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. *Can J Clin Pharmacol.* (2009) 16:e407.
- Armour M, Ee CC, Hao J, Wilson TM, Yao SS, Smith CA. Acupuncture and acupressure for premenstrual syndrome. *Cochrane Database Syst Rev.* (2018) 8:CD005290. doi: 10.1002/14651858.CD005290.pub2
- Buttner MM, Mott SL, Pearlstein T, Stuart S, Zlotnick C, O'Hara WM. Examination of premenstrual symptoms as a risk factor for depression in postpartum women. *Arch Womens Mental Health.* (2013) 16:219–25. doi: 10.1007/s00737-012-0323-x
- Kepple L, Lee EE, Haq N, Rubinow DR, Schmidt PJ. History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder. J Clin Psychiatry. (2016) 77:e415–20. doi: 10.4088/JCP.15m09779
- Sylvén SM, Ekselius L, Sundström-Poromaa I, Skalkidou A. Premenstrual syndrome and dysphoric disorder as risk factors for postpartum depression. *Acta Obstetricia Et Gynecol Scand.* (2013) 92:178–84. doi: 10.1111/aogs.12041
- 57. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. *J Clin Psychiatry*. (1997) 58(Suppl. 15):19–25.

- Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol.* (2014) 35:320–30. doi: 10.1016/j.yfrne.2014.05.004
- Dubol M, Epperson CN, Lanzenberger R, Sundstrom-Poromaa I, Comasco E. Neuroimaging premenstrual dysphoric disorder: a systematic and critical review. *Front Neuroendocrinol.* (2020) 57:100838. doi: 10.1016/j.yfrne.2020.100838
- 60. Lippman RW. Nephrotic syndrome with exaggerated premenstrual water and salt retention. *Am J Med.* (1950) 8:686–7. doi: 10.1016/0002-9343(50)90314-7
- Morton JH. Premenstrual tension. Am J Obstetrics Gynecol. (1950) 60:343–52. doi: 10.1016/0002-9378(50)90475-3
- Argonz J, Abinzano C. Premenstrual tension treated with vitamin A. J Clin Endocrinol Metab. (1950) 10:1579–90. doi: 10.1210/jcem-10-12-1579
- Miura J, Honma R. Daytime sleepiness in relation to gender and premenstrual symptoms in a sample of Japanese college students. *Sleep Biol Rhythms.* (2020) 18:3–8. doi: 10.1007/s41105-019-00236-x
- 64. Joyce KM, Good KP, Tibbo P, Brown J, Stewart SH. Addictive behaviors across the menstrual cycle: a systematic review. *Arch Women's Mental Health.* (2021). doi: 10.1007/s00737-020-01094-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Gao, Gao, Sun, Cheng, An and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.